|
Novel Breast Cancer Therapies: CDK4/6 Inhibitors
STATEMENT OF NEED
Breast cancer is the most common cancer diagnosed in women, with 287,850 new cases and 43,250 deaths predicted to occur in 2022 (ACS, 2022). Making up 73% of cases, hormone receptor (HR)"positive/human epidermal growth factor receptor 2 (HER2)"negative disease is the most common subtype of breast cancer (ACS, 2019). Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are a novel therapeutic option for patients with HR-positive, HER2-negative advanced breast cancer. T... |
|
|
Novel Breast Cancer Therapies: PI3K Inhibitors
STATEMENT OF NEED
Breast cancer is the most diagnosed cancer in women, with hormone receptor (HR)"positive/human epidermal growth factor receptor 2 (HER2)"negative breast cancer being the most common subtype, making up 73% of cases (ACS, 2019). In breast cancer, phosphatidylinositol-3-kinase (PI3K) overactivation is often associated with an activating mutation in the catalytic alpha subunit of PI3K (PIK3CA). These activating mutations occur in more than one third of breast cancers... |
|
|
Pathology and Oncology Expert Perspectives in the Management of Triple-Negative Breast Cancer: Case Explorations and Answers to FAQs
STATEMENT OF NEED
Triple-negative breast cancer (TNBC) is an aggressive disease that accounts for approximately 10% to 15% of breast cancer diagnoses and is characterized by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2). TNBC is more common in Black women and in women under the age of 40 (ACS, 2023). Compared with other subtypes of invasive breast cancer, TNBC has high rates of metastasis and a poor prognosis. Due to the lack ... |
|
|
Evolving Treatment Paradigms in HR-Positive, HER2-Negative Breast Cancer: Integrating the Latest Evidence Into Clinical Practice
Target Audience
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
Program Overview
Advances in therapy for patients with hormone receptor"positive (HR+)/human epidermal growth factor receptor 2"negative (HER2-) breast cancer have the potential to reduce disease recurrence and risk of mortality. However, the complex and evolving treatment landscap... |
|
|
Animal-Assisted Therapy and the Healing Power of Pets
This is the first course in a three part series and includes the story of Deirdre Rand’s journey with her animal companions and the lessons learned from the challenges and rewards of those relationships. Also discussed are temperament, socialization and training; the role of the neurohormone oxytocin in strengthening the human-companion animal bond; the founding of the three major organizations which register volunteer handler/therapy teams, along with the contributions of key historic figur... |
|
|
Addressing Health Care Disparities and Improving Patient Outcomes in Prostate Cancer: Expert Perspectives on Optimizing ADT
Prostate cancer is the leading cause of cancer and the second leading cause of cancer death in men in the United States. Medical androgen deprivation therapy (ADT) is the standard of care for advanced prostate cancer but may be associated with a broad range of adverse effects. Increased risk of cardiovascular (CV) events is among the most serious, as CV disease is the most common non-cancer cause of death in prostate cancer patients. Although evidence-based guidelines on ADT selection and CV r... |
|
|
Navigating New Evidence in the Treatment of HER2-Expressing Metastatic Breast Cancer in Rural and Underserved Communities
Target Audience
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
Program Overview
Over the past decades, the emergence of novel targeted therapies in combination with endocrine therapy has improved outcomes for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. However, oncology clinicians in rural and ... |
|
|
“THEY TOO SHALL PASS: A JOURNEY THROUGH CARING FOR ADULT TRANSGENDER PATIENTS”
CLASS OVERVIEW
This CE will allow providers to gain a solid foundation regarding transgender healthcare and the skills necessary to provide healthcare for transgender patients in a safe, supportive and welcoming environment
EDUCATIONAL/LEARNING OBJECTIVES:
1. Recognize and apply gender confirming and gender-nonconforming terminology to current practice
2. Review epidemiology of the LGBTQIA+ population
3. Design a welcoming, safe, and supportive environment for patients within the LGBTQI... |
|